...
首页> 外文期刊>Journal of Medicinal Chemistry >Application of CoMFA and CoMSIA 3D-QSAR and Docking Studies in Optimization of Mercaptobenzenesulfonamides as HIV-1 Integrase Inhibitors
【24h】

Application of CoMFA and CoMSIA 3D-QSAR and Docking Studies in Optimization of Mercaptobenzenesulfonamides as HIV-1 Integrase Inhibitors

机译:CoMFA和CoMSIA 3D-QSAR的应用以及对接研究在优化巯基苯磺酰胺作为HIV-1整合酶抑制剂中的应用

获取原文
获取原文并翻译 | 示例
           

摘要

An essential step in the HIV life cycle is integration of the viral DNA into the host chromosome. This step is catalyzed by a 32-kDa viral enzyme HIV integrase (IN). HIV-1 IN is an important and validated target, and the drugs that selectively inhibit this enzyme, when used in combination with reverse transcriptase (RT) and protease (PR) inhibitors, are believed to be highly effective in suppressing the viral replication. IN catalyzes two discrete enzymatic processes referred to as 3' processing and DNA strand transfer. As a part of a study to optimize new lead molecules we previously identified from a series of 2-mercaptobenzenesulfonamides (MBSAs), we applied three-dimensional quantitative structure-activity relationship methods, comparative molecular field analysis (CoMFA), and comparative molecular similarity indices analysis (CoMSIA) to training sets of up to 66 compounds. Two different conformational templates were used: Conf-d, obtained from docking into the HIV-1 IN active site and Conf-s obtained by a systematic conformational search, using lead compounds 1 and 14, respectively. Reliable models of good predictive power were obtained after removal of compounds with high residuals. The Conf-s models tended to perform better than the Conf-d models. Cross-validated coefficients (q~2) of up to 0.719 (strand transfer CoMSIA, Conf-s) regression coefficients (r~2) of up to 0.932 (strand transfer CoMSIA, Conf-d) were obtained, with the number of partial least squares (PLS) components varying from 3 to 6, and the number of outliers being 4 in most of the models. Because all biological data were determined under exactly the same conditions using the same enzyme preparation, our predictive models are promising for drug optimization. Therefore, these results combined with docking studies were used to guide the rational design of new inhibitors. Further synthesis of 12 new analogues was undertaken, and these were used as a test set for validation of the quantitative structure-activity relationship (QSAR) models. For compounds with closely related structures, binding energies given by the FlexX scoring function correlated with HIV-1 IN inhibitory activity.
机译:HIV生命周期的重要步骤是将病毒DNA整合到宿主染色体中。此步骤由32 kDa病毒酶HIV整合酶(IN)催化。 HIV-1 IN是重要且经过验证的靶标,与逆转录酶(RT)和蛋白酶(PR)抑制剂组合使用时,选择性抑制该酶的药物被认为在抑制病毒复制方面非常有效。 IN催化两个离散的酶促过程,称为3'处理和DNA链转移。作为优化我们先前从一系列2-巯基苯磺酰胺(MBSA)中识别出的先导分子的研究的一部分,我们应用了三维定量结构-活性关系方法,比较分子场分析(CoMFA)和比较分子相似性指数分析(CoMSIA),以训练多达66种化合物。使用了两种不同的构象模板:分别通过对接至HIV-1 IN活性位点获得的Conf-d和通过系统构象搜索分别使用前导化合物1和14获得的Conf-s。去除具有高残留物的化合物后,可获得具有良好预测能力的可靠模型。 Conf-s模型的性能往往优于Conf-d模型。交叉验证系数(q〜2)最高为0.719(链转移CoMSIA,Conf-s)回归系数(r〜2)最高为0.932(链转移CoMSIA,Conf-d),其中部分数量在大多数模型中,最小二乘(PLS)分量从3到6不等,离群数为4。由于所有生物学数据都是在完全相同的条件下使用相同的酶制剂测定的,因此我们的预测模型有望优化药物。因此,这些结果与对接研究相结合,可用于指导新型抑制剂的合理设计。进行了12种新类似物的进一步合成,并将它们用作验证定量构效关系(QSAR)模型的测试集。对于结构密切相关的化合物,由FlexX评分功能提供的结合能与HIV-1 IN抑制活性相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号